These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 36709298)
1. Risk factors for herpes zoster: should people with asthma or COPD be vaccinated? Safonova E; Yawn BP; Welte T; Wang C Respir Res; 2023 Jan; 24(1):35. PubMed ID: 36709298 [TBL] [Abstract][Full Text] [Related]
2. Public health impact of herpes zoster vaccination on older adults in Hong Kong. Chan PKS; Wong MCS; Chan M; Ching K; Giannelos N; Ng C Hum Vaccin Immunother; 2023 Dec; 19(1):2176065. PubMed ID: 36854447 [TBL] [Abstract][Full Text] [Related]
3. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations. Parikh R; Widenmaier R; Lecrenier N Expert Rev Vaccines; 2021 Sep; 20(9):1065-1075. PubMed ID: 34311643 [TBL] [Abstract][Full Text] [Related]
4. An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine. Pirrotta P; Tavares-Da-Silva F; Co M; Lecrenier N; Hervé C; Stegmann JU Drug Saf; 2021 Dec; 44(12):1341-1353. PubMed ID: 34622421 [TBL] [Abstract][Full Text] [Related]
5. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults. McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218 [TBL] [Abstract][Full Text] [Related]
6. Public health impact of herpes zoster vaccination on older adults in Singapore: a modeling study. Oh H; Tan C; Williams C; Giannelos N; Ng C Hum Vaccin Immunother; 2024 Dec; 20(1):2348839. PubMed ID: 38804600 [TBL] [Abstract][Full Text] [Related]
7. Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies. Mwakingwe-Omari A; Lecrenier N; Naficy A; Curran D; Posiuniene I Hum Vaccin Immunother; 2023 Dec; 19(3):2278362. PubMed ID: 37965770 [TBL] [Abstract][Full Text] [Related]
8. Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer. Curran D; Patterson BJ; Carrico J; Salem A; La EM; Lorenc S; Hicks KA; Poston S; Carpenter CF Hum Vaccin Immunother; 2023 Dec; 19(1):2167907. PubMed ID: 36880669 [TBL] [Abstract][Full Text] [Related]
9. Herpes zoster in Belgium: a new solution to an old problem. Nikkels AF; Schoevaerdts D; Kauffmann F; Strubbe F; Bensemmane S Acta Clin Belg; 2024 Jun; 79(3):205-216. PubMed ID: 38781037 [TBL] [Abstract][Full Text] [Related]
10. Herpes Zoster Ophthalmicus: Presentation, Complications, Treatment, and Prevention. Litt J; Cunningham AL; Arnalich-Montiel F; Parikh R Infect Dis Ther; 2024 Jul; 13(7):1439-1459. PubMed ID: 38834857 [TBL] [Abstract][Full Text] [Related]
11. Association of asthma and herpes zoster, the role of vaccination: A literature review. Shrestha AB; Umar TP; Mohammed YA; Aryal M; Shrestha S; Sapkota UH; Adhikari L; Shrestha S Immun Inflamm Dis; 2022 Nov; 10(11):e718. PubMed ID: 36301037 [TBL] [Abstract][Full Text] [Related]
12. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015. Miller ER; Lewis P; Shimabukuro TT; Su J; Moro P; Woo EJ; Jankosky C; Cano M Hum Vaccin Immunother; 2018; 14(8):1963-1969. PubMed ID: 29580194 [TBL] [Abstract][Full Text] [Related]
13. Vaccines for preventing herpes zoster in older adults. Gagliardi AM; Andriolo BN; Torloni MR; Soares BG; de Oliveira Gomes J; Andriolo RB; Canteiro Cruz E Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31696946 [TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany. Curran D; Van Oorschot D; Matthews S; Hain J; Salem AE; Schwarz M Hum Vaccin Immunother; 2021 Dec; 17(12):5296-5303. PubMed ID: 34905463 [TBL] [Abstract][Full Text] [Related]
15. Breadth and Functionality of Varicella-Zoster Virus Glycoprotein-Specific Antibodies Identified after Zostavax Vaccination in Humans. Sullivan NL; Reuter-Monslow MA; Sei J; Durr E; Davis CW; Chang C; McCausland M; Wieland A; Krah D; Rouphael N; Mehta AK; Mulligan MJ; Pulendran B; Ahmed R; Vora KA J Virol; 2018 Jul; 92(14):. PubMed ID: 29743372 [TBL] [Abstract][Full Text] [Related]
16. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials. López-Fauqued M; Co-van der Mee M; Bastidas A; Beukelaers P; Dagnew AF; Fernandez Garcia JJ; Schuind A; Tavares-da-Silva F Drug Saf; 2021 Jul; 44(7):811-823. PubMed ID: 34115324 [TBL] [Abstract][Full Text] [Related]
17. A systematic literature review to assess the burden of herpes zoster disease in China. Yin D; Van Oorschot D; Jiang N; Marijam A; Saha D; Wu Z; Tang H; Diaz-Decaro J; Watson P; Xie X; Ren Y; He Y; Feng Y Expert Rev Anti Infect Ther; 2021 Feb; 19(2):165-179. PubMed ID: 32997550 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence. Parikh R; Singer D; Chmielewski-Yee E; Dessart C Hum Vaccin Immunother; 2023 Dec; 19(3):2263979. PubMed ID: 37967254 [TBL] [Abstract][Full Text] [Related]
19. Shingrix for Herpes Zoster: A Review. Shah RA; Limmer AL; Nwannunu CE; Patel RR; Mui UN; Tyring SK Skin Therapy Lett; 2019 Jul; 24(4):5-7. PubMed ID: 31339679 [TBL] [Abstract][Full Text] [Related]
20. How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be? Han R; Gomez JA; de Veras B; Pinto T; Guzman-Holst A; Nieto J; van Oorschot DAM Hum Vaccin Immunother; 2023 Dec; 19(1):2164144. PubMed ID: 36821856 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]